9 things to know about Boston Scientific

Here are nine things to know about medical device manufacturer Boston Scientific, based in Marlborough, Mass.

1. Boston Scientific's endoscopy segment is the most profitable of its MedSurg branch, with revenues of $1.62 billion in fiscal year 2017.

2. Trefis analysts estimate Boston Scientific's endoscopy division makes up 20 percent of its total portfolio. The market firm's analysts believe the company is turning to endoscopy to reverse losses its cardiovascular medical device business fielded.

3. John Abele and Pete Nicholas co-founded Boston Scientific in 1979 as a holding company to purchase Medi-Tech, an interventional medicine company that Mr. Abele joined in 1969.

4. The company offers more than 1,500 technologies to treat GI and pulmonary diseases.

5. In March, Boston Scientific acquired EMcision to expand its GI endoscopy offerings. EMcision was a privately held company in the U.K. and Canada that created the Habib EndoHPB probe, a novel endoscopic bipolar radiofrequency device designed to help coagulate tissue in the GI tract.

6. Boston Scientific reported $7 billion in fiscal year 2017 sales.

7. The company donated 1 percent of colonic stent, snare, clip and biopsy forceps sales made in March to the Colorectal Cancer Alliance, a non-profit organization championing prevention, funding research and providing patient support services.

8. Boston Scientific is active on four continents, with more than 20 portfolio companies and over $250 million in investments.

9. In 2016, Boston Scientific acquired Alpharetta, Ga.-based EndoChoice for $210 million in cash.

More articles on gastroenterology:

IU Health, Southern New Hampshire Health & more: 3 GI practices in the news

Outcome Health, Salix Pharmaceuticals & more — 5 GI company key notes

The International Foundation for Functional Gastrointestinal Disorders raises awareness for IBS: 5 insights

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.